SARS-CoV-2 and COVID-19 Research

This paper presents EscapeMap, a framework for predicting and designing SARS-CoV-2 variants that escape antibodies, and identifies antibody combinations less prone to simultaneous escape.

This study examines how maternal vaccination timing affects antibody clonotype transfer to newborns, finding that earlier vaccination leads to more diverse but less persistent clonotypes, while later vaccination results in more persistent, affinity-matured antibodies in cord blood.

This paper develops a recombinant SARS-CoV-2 virus expressing reporter genes to track viral infection in wild-type mice, showing it can be used for vaccine and antiviral research without needing transgenic models.

The paper develops a method to detect recombination breakpoints and signs of human-made manipulation in viral sequences, finding no evidence of such manipulation in SARS-CoV-1, MERS-CoV, or SARS-CoV-2.

This paper creates a super-resolution atlas of SARS-CoV-2 infection, revealing protease-dependent organelle maturation, dsRNA structures, and structural proteins, with implications for antiviral strategies.

This study analyzes serum IgG repertoires in vaccinated cystic fibrosis patients, identifying convergent antibodies that target the SARS-CoV-2 receptor-binding domain and show strain-specific neutralization.

The paper identifies a conserved linear epitope in the SARS-CoV-2 N protein recognized by mAb N179, explaining its variant resistance and diagnostic reliability.

This study shows that dirty mice, with broad microbial exposure, better model human immune responses to SARS-CoV-2 mRNA vaccines, showing reduced antibody titers and faster waning compared to SPF mice.

This study evaluates the immunogenicity of an LP.8.1-adapted BNT162b2 vaccine against JN.1 sublineages, showing higher neutralizing antibody responses compared to other adapted vaccines.

This paper identifies SARS-CoV-2 PLpro as a driver of epithelial stress and tissue damage across species by activating metabolic and inflammatory pathways in Drosophila and mammalian models.

This study shows that the SARS-CoV-2 Spike H655Y mutation changes protease preference but does not determine cellular tropism, with RBD interactions being more critical for upper airway adaptation.

This study determines the crystal structures of HKU5-CoV Mpro with and without inhibitors, revealing conserved binding mechanisms and informing antiviral drug development.

This study assesses cross-neutralisation of sarbecoviruses by COVID-19 vaccines in older adults, finding reduced neutralisation of Omicron variants and some animal sarbecoviruses but enhanced neutralisation of specific bat and pangolin coronaviruses.

ConvMut identifies recurrent mutations in SARS-CoV-2 phylogenies to aid in vaccine and antibody design.

The paper investigates how mutations in SARS-CoV-2 M and N proteins balance viral particle assembly and immune evasion through co-evolution.

This paper develops AENCS to engineer antibodies targeting glycosylated epitopes, demonstrating ACC01's 24-fold improved neutralization against SARS-CoV-2 variants.

The paper analyzes over 3000 SARS-CoV-2 sequences from chronic infections to identify mutation patterns linked to viral persistence and long Covid.

This study identifies the role of 5' and 3' UTRs in SARS-CoV-2 genome packaging by showing their interaction with the PS9 element and enhancing packaging efficiency.

The paper evaluates adjuvant effects on immune responses in virosome-based SARS-CoV-2 vaccines, finding distinct impacts on humoral and cellular immunity.

The paper compares three data analysis methods for MERS-CoV MPro inhibitors, finding that modeling the complete concentration-response curve best predicts cellular efficacy.

This study examines immune responses in adults with COVID-19 who received or did not receive nirmatrelvir-ritonavir, finding no differences in immune markers between those with and without virologic rebound.

This study shows that human cardiomyocytes with trisomy 21 are more susceptible to SARS-CoV-2 infection and show an amplified immune response compared to euploid controls.

The paper analyzes mutations in SARS-CoV-2 RBDs using deep mutational scanning to identify changing amino acid preferences and epistatic interactions across variants.

This paper develops a human immune system mouse model to study SARS-CoV-2 dissemination and immune responses, finding that human T cells suppress innate immunity and allow viral persistence.

This study identifies recurrent saltational events in SARS-CoV-2 evolution, linking them to persistent human infections rather than zoonotic sources.

This study identifies multiple dispersed packaging signals in the SARS-CoV-2 genome that cooperate to direct RNA packaging into virions, revealing a dynamic mechanism for coronavirus genome assembly.

This study shows SARS-CoV-2 E-protein activates CD8+ T cells in mouse lungs via TLR2, observed using intravital microscopy and ex vivo stimulation.

This study shows that disrupting both NSP3 and nucleocapsid SG antagonism reduces SARS-CoV-2 replication and disease, suggesting stress granule activation as a therapeutic target.

This study investigates how TMPRSS2 affects ACE2 trafficking and shedding, showing that TMPRSS2 interaction alters ACE2 processing and glycosylation impacts these effects in vivo.

This paper develops a stable reporter coronavirus for studying transcriptional responses in infected and bystander cells, finding that infection primarily triggers inflammatory rather than interferon-mediated host responses.